[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-onset-hereditary-spastic-paraplegia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-onset-hereditary-spastic-paraplegia":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100558657","spastic-paraplegia---centers-of-excellence-research-network-100558657",false,"NCT06553976","Spastic Paraplegia - Centers of Excellence Research Network","Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) - Natural History Study Pilot","SP-CERN","Inclusion Criteria:\n\n* Male or female patients of all ages with a clinical and molecular diagnosis of hereditary spastic paraplegia type 4 (SPG4, SPAST) or hereditary spastic paraplegia type 5A (SPG5A, CYP7B1).\n\nExclusion Criteria:\n\n* Not having such a diagnosis and\u002For not being related to such individual.","ALL",{"count":19,"type":20},100,"ESTIMATED","2 Years","OBSERVATIONAL","The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).",[25,26,27,28,29,30,31,32,33],"Hereditary Spastic Paraplegia","Primary Lateral Sclerosis","SPG4","SPG5A","Spastic Paraplegia 4","Spastic Paraplegia 5A","Early Onset Hereditary Spastic Paraplegia","Neuromuscular Diseases","Spastic Paraplegia, Hereditary","RECRUITING","2026-03-16",{"date":37,"type":38},"2026-03-18","ACTUAL",{"date":40,"type":38},"2024-06-04",{"date":42,"type":20},"2027-06-04",{"name":44,"class":45},"Boston Children's Hospital","OTHER",11,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":4,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":70,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100417217","registry-and-natural-history-study-for-early-onset-hereditary-spastic-paraplegia-100417217","NCT04712812","Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia","Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP)","HSP","Inclusion Criteria:\n\n* Onset of hereditary spastic paraplegia symptoms before the age of 18 years\n* Under the age of 30 years old\n* Must have a genetically confirmed variant in HSP-related genes and a relative of an individual with a confirmed diagnosis (if applicable).\n\nExclusion Criteria:\n\n* Not having such a diagnosis and\u002For not being related to such individual",true,"30 Years",{"count":58,"type":20},700,"4 Years","The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and\u002For blood and\u002For saliva) from male and female patients, under the age of 30, who exhibited early onset symptoms of HSP with (1) a clinical diagnosis of hereditary spastic paraplegia and (2) the presence of variants in HSP related genes and\u002For be a relative of a person with such a diagnosis. Currently, the treatment for this disorder is generally symptomatic and available therapies improve quality of life, but are grossly inefficient in slowing the disease progression. Access to the registry information will be limited to the study staff who are responsible for recruitment and maintenance of the registry. We hope that recruitment into the registry for studies will advance knowledge of the causes, clinical course, diagnosis, and treatment of these conditions.",[25,62,63,64,65,66,31,27,67,68,69],"SPG47","SPG50","SPG51","SPG52","AP4-related Hereditary Spastic Paraplegia","SPG3A","SPG15","SPG11",[71,72,73,74,75,76,77,53,78,79],"AP4-HSP","AP4","SPG","AP-4","AP-4-HSP","Spastic Paraplegia","Adapter Protein 4","Early onset","Early onset HSP",{"date":37,"type":38},{"date":82,"type":38},"2020-04-27",{"date":84,"type":20},"2030-12-31",{"name":44,"class":45},1]